Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-38431055 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose |
| 002 | ACTIVE_COMPARATOR | Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose |
| 003 | EXPERIMENTAL | JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose |
| 004 | PLACEBO_COMPARATOR | Placebo Placebo suspension and placebo capsule administered as single doses |
| Name | Type | Description |
|---|---|---|
| JNJ-38431055 | DRUG | Liquid suspension of JNJ-38431055 administered as a single dose |
| Sitagliptin 100 mg | DRUG | Capsule containing 100 mg of sitagliptin administered as a single dose |
| JNJ-38431055 + Sitagliptin 100 mg | DRUG | Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose |
| Placebo | DRUG | Placebo suspension and placebo capsule administered as single doses |
Inclusion Criteria: * Body Mass Index (BMI) between 27.0 and 38.0 kg/m2 (inclusive) * Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests * Men must agree to use a double barrier method of birth control (e.g., condom fo...
JNJ-38431055 is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It is in Phase 1 clinical development, and it has been studied in healthy male volunteers to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
JNJ-38431055 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical trials for Type 2 Diabetes Mellitus.
JNJ-38431055 is in Phase 1 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both involving healthy male volunteers.
JNJ-38431055 has been studied in two completed Phase 1 clinical trials. NCT00910923 evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics in 37 healthy male volunteers. NCT01054118 evaluated single doses of JNJ-38431055, sitagliptin, and their co-administration in 18 healthy male volunteers in the United States.
No, JNJ-38431055 is not the same as sitagliptin. Sitagliptin is a separate drug that was used as a comparator in a clinical trial (NCT01054118) to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ-38431055, sitagliptin, and their co-administration.